What is STOK's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.60B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for STOK?

P/E (TTM) is n/a and 52-week range is $20.32 to $40.22 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s STOK figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for STOK?

The company profile lists revenue (TTM) near $26M, net income (TTM) near $-19.61B, EPS (TTM) near $-3.36 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Stoke Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Bedford, Massachusetts, US, 62.3M shares outstanding, ISIN US86150R1077 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Stoke Therapeutics Inc

$STOK

Health Care · Biotechnology

IR Run Scenarios

$24.74

+3.30%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 170 full-time employees. The company went IPO on 2019-06-19. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The firm is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Employees

170

Website

www.stoketherapeutics.com/

IPO

2019-06-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)